Encouraging Preclinical Results Generated with Sareum’s TYK2/JAK1 Inhibitors in a Disease Model of Lupus
Sareum Holdings PLC (SAR.L) Research Update
Symphony Environment (SYM.L) Positive Bovine Coronavirus Test Results
Symphony Environmental Technologies Plc (AIM: SYM), is pleased to announce positive antiviral test results from Eurofins Laboratories for its d2p antimicrobial masterbatch technology.
TPI provides its latest research note on Midatech Pharma plc (MTPH.L).
Midatech has today announced its signing of further research collaboration, this time with an unnamed ‘global pharmaceutical’ group that wishes to utilise its Q-Sphera™ platform in order to improve/optimise the
Midatech Pharma PLC (MTPH.L) Collaboration for the Q-Sphera platform
Midatech Pharma’s next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company.
Synairgen plc (SNG.L) Clarification Regarding COVID-19 Trial
Southampton, UK – 21 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, issues clarification with respect
Tiziana Life Sciences plc (TILS.L) Director Appointment
New York/London, 20 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules
Synairgen plc (SNG.L) positive results from trial of SNG001 in hospitalised COVID-19 patients
Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo Patients who received SNG001 were more than twice as likely to recover from COVID-19
Share Talk, Bulletin Board Heroes – Pharma Special, Sunday 19th July 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Here is our pick of the
Verona Pharma plc (VRP.L) $200 Million in Oversubscribed Private Placement and Subscription
Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has raised approximately $200 million (£159 million*).
Tiziana Life Sci PLC (TILS.L) Submission of Patent Application
Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy
Open Orphan PLC (ORPH.L) Option to Acquire CHIMagents Limited
Cathal Friel, Executive Chairman of Open Orphan, said:
